Trial Profile

Phase Ib/IIa Safety and Efficacy of PM8002, a Bispecific Antibody Targeting PD-L1 and VEGF-A, as a Monotherapy in Patients With Advanced Solid Tumors

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 09 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs PM-8002 (Primary)
Indications Cervical cancer; Non-small cell lung cancer; Ovarian cancer; Renal cell carcinoma; Solid tumours
Focus Adverse reactions; Therapeutic Use
Sponsors Biotheus

05 Dec 2024 Planned End Date changed from 30 Nov 2024 to 30 Nov 2025.
05 Dec 2024 Planned primary completion date changed from 30 Nov 2023 to 30 Nov 2025.
05 Sep 2024 According to a BioNTech media release, two oral presentations and one poster will provide clinical data updates for cohorts with advanced non-small cell lung cancer (NSCLC), and advanced renal cell carcinoma, at the European Society for Molecular Oncology (ESMO) Congress 2024 in Barcelona, Spain from September 13-17, 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com